Topic: Pulmonary Hypertension
Gilead’s recent troubles in hepatitis C aside, the company isn't challenge-free. It has a big patent loss coming this year for Letairis, approved in 2007 and used to treat pulmonary arterial hypertension.
While support from drugmakers can be helpful for patients, sometimes support from fellow patients can be even more helpful. So Bayer is offering both.
Gilead Sciences is said to be evaluating United Therapeutics, although it finds itself in competition with GlaxoSmithKline and perhaps others.
The European Medicines Agency, after a review, said Actelion’s new pulmonary arterial hypertension med Uptravi is in the clear.
J&J is counting on new buy Actelion’s pulmonary arterial hypertension meds to provide a top-line boost. But one of them may have just hit a safety snag.
Among the many meds that’ll lose patent protection in the U.S. this year are 10 drugs that each contribute in a big way for top drugmakers. Eli Lilly, Pfizer, Takeda, Bristol-Myers Squibb and Gilead Sciences are set to hit the patent cliff this year with some of their respective big sellers.
Could Actelion's $26 billion-plus deal talks with J&J fall through, now that its PAH drug Opsumit has fallen short in a study designed to grow its market? Not likely, analysts said Monday.
Bayer has long counted pulmonary arterial hypertension newcomer Adempas among its Big 5 growth products. But should it?